Ulcer and Gastritis

The literature on peptic ulcer and gastritis in 2000 again focused on the topics of Helicobacter pylori, nonsteroidal anti-inflammatory drugs (NSAIDs), and gastric cancer. New diagnostic tests for H. pylori infection have been evaluated, and rescue therapies for failed H. pylori eradication have been tested. The causal relationship between H. pylori infection and nonulcer dyspepsia, gastric cancer, gastroesophageal reflux disease, and NSAID-related ulcers remained heated topics of debate. In 2000, landmark clinical trials and meta-analyses were published addressing these issues. The role of endoscopy in managing nonulcer dyspepsia was better defined. The role of H. pylori eradication in NSAID/aspirin users was reexamined in high-risk patients. Clinical benefit was finally confirmed for specific inhibitors of cyclooxygenase-2 (COX-2). The millennium year turned out to be a very important one in the advancement of knowledge in this field.

References

• 1 Nishikawa K, Sugiyama T, Kato M. et al . A prospective evaluation of new rapid urease tests before and after eradication treatment of Helicobacter pylori, in comparison with histology, culture and ¹³C-urea breath test.  Gastrointest Endosc. 2000;  51 164-168
• 2 Laine L, Sugg J, Suchower L, Neil G. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori.  Gastrointest Endosc. 2000;  51 664-669
• 3 Oderda G, Rapa A, Marinello D. et al . Usefulness of Helicobacter pylori stool antigen test to monitor response to eradication treatment in children.  Aliment Pharmacol Ther. 2001;  15 203-206
• 4 Ishihara S, Kaji T, Kawamura A. et al . Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy.  Aliment Pharmacol Ther. 2000;  14 611-614
• 5 Vaira D, Malfertheiner P, Mégraud F. et al . Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group.  Am J Gastroenterol. 2000;  95 925-929
• 6 Costa F, Mumolo M G, Bellini M. et al . Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools.  Aliment Pharmacol Ther. 2001;  15 395-401
• 7 Forne M, Dominguez J, Fernandez-Banares F. et al . Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up.  Am J Gastroenterol. 2000;  95 2200-2205
• 8 Calvet X, Garcia N, Lopez T. et al . A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.  Aliment Pharmacol Ther. 2000;  14 603-609
• 9 Calvet X, Gene E, Lopez T, Gisbert J P. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.  Aliment Pharmacol Ther. 2001;  15 1067-1076
• 10 Armuzzi A, Cremonini F, Bartolozzi F. et al . The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy.  Aliment Pharmacol Ther. 2001;  15 163-169
• 11 Gomollon F, Sicilia B, Ducons J A. et al . Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients.  Aliment Pharmacol Ther. 2000;  14 1335-1338
• 12 Perri F, Festa V, Clemente R. et al . Randomized study of two “rescue” therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.  Am J Gastroenterol. 2001;  96 58-62
• 13 Miwa H, Hirai S, Nagahara A. et al . Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients: a double-blind placebo-controlled study.  Aliment Pharmacol Ther. 2000;  14 317-324
• 14 Hsu P I, Lai K H, Tseng H H. et al . Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.  Aliment Pharmacol Ther. 2001;  15 195-201
• 15 Sontag S J, Connell S, Schnell T. et al . Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.  Am J Gastroenterol. 2001;  96 1390-1395
• 16 Laine L, Schoenfeld P, Fennerty M B. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: a meta-analysis of randomized, controlled trials.  Ann Intern Med. 2001;  134 361-369
• 17 Moayyedi P, Feltbower R, Crocombe W. et al . The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group.  Aliment Pharmacol Ther. 2000;  14 719-728
• 18 Blum A L, Arnold R, Stolte M. et al . Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. The Frosch Study Group.  Gut. 2000;  47 473-480
• 19 Delaney B C, Wilson S, Roalfe A. et al . Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care.  Br Med J. 2001;  322 898-901
• 20 Lassen A T, Pedersen F M, Bytzer P, de Muckadell O BS. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.  Lancet. 2000;  356 455-460
• 21 Delaney B C, Wilson S, Roalfe A. et al . Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care.  Lancet. 2000;  356 1965-1969
• 22 Sung J J, Leung W K, Go M Y. et al . Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions.  Am J Pathol. 2000;  157 729-735
• 23 El Omar E M, Carrington M, Chow W H. et al . Interleukin-1 polymorphisms associated with increased risk of gastric cancer.  Nature. 2000;  404 398-402
• 24 Ohkusa T, Fujiki K, Takashimizu I. et al . Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.  Ann Intern Med. 2001;  134 380-386
• 25 Sung J J, Lin S R, Ching J Y. et al . Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study.  Gastroenterology. 2000;  119 7-14
• 26 Annibale B, Aprile M R, Ambra G. et al . Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia.  Aliment Pharmacol Ther. 2000;  14 625-634
• 27 Vaezi M F, Falk G W, Peek R M. et al . CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus.  Am J Gastroenterol. 2000;  95 2206-2211
• 28 Hamada H, Haruma K, Mihara M. et al . High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis.  Aliment Pharmacol Ther. 2000;  14 729-735
• 29 Schwizer W, Thumshirn M, Dent J. et al . Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.  Lancet. 2001;  357 1738-1742
• 30 Schenk B E, Kuipers E J, Nelis G F. et al . Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.  Gut. 2000;  46 615-621
• 31 Sharma P, Topalovski M, Mayo M S, Sampliner R E, Weston A P. Helicobacter pylori eradication dramatically improves inflammation in the gastric cardia.  Am J Gastroenterol. 2000;  95 3107-3111
• 32 Godil A, DeGuzman L, Schilling R C. et al . Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer.  Gastrointest Endosc. 2000;  51 146-151
• 33 Goldstein J L, Correa P, Zhao W W. et al . Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.  Am J Gastroenterol. 2001;  96 1019-1027
• 34 Silverstein F E, Faich G, Goldstein J L. et al . Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial.  JAMA. 2000;  284 1247-1255
• 35 Bombardier C, Laine L, Reicin A. et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 1520-1528
• 36 Lanas A, Bajador E, Serrano P. et al . Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs and the risk of upper gastrointestinal bleeding.  N Engl J Med. 2000;  343 834-839
• 37 Chan F K, To K F, Ng Y P. et al . Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis.  Aliment Pharmacol Ther. 2001;  15 187-193
• 38 Feldman M, Cryer B, Mallat D, Go M F. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.  Am J Gastroenterol. 2001;  96 1751-1757
• 39 Chan F KL, Chung S CS, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
• 40 Scheiman J M, Bandekar R R, Chernew M E, Fendrick A M. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis.  Aliment Pharmacol Ther. 2001;  15 63-71
• 41 Lau J YW, Sung J JY, Lee K KC. et al . Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.  N Engl J Med. 2000;  343 310-316
• 42 Hawkey G M, Cole A T, McIntyre A S. et al . Drug treatments in upper gastrointestinal bleeding: value of endoscopic findings as surrogate end points.  Gut. 2001;  49 372-379